Thyrocare Technologies · NSE: THYROCARE · BSE: 539871

Q4 FY26 results · Jan–Mar 2026

Thyrocare Technologies reported revenue from operations of ₹223.95 crore (up 19.7% from Q4 FY25) and net profit of ₹48.70 crore (up 125.8% from Q4 FY25) for Q4 FY26 (Jan–Mar 2026), on a consolidated basis.

Consolidated · ₹ crore
Item	Q4 FY26	Q4 FY25	YoY	Q3 FY26	QoQ
Revenue from operations	223.95	187.16	+19.7%	195.53	+14.5%
Other income	4.31	4.59	−6.1%	4.98	−13.5%
Total income	228.26	191.75	+19.0%	200.51	+13.8%
Profit before share of associates & JVs and tax	63.85	47.82	+33.5%	35.11	+81.9%
Share of profit/(loss) of associates & JVs	0.58	(0.63)		0.28
Net profit for the period	48.70	21.57	+125.8%	28.05	+73.6%
Attributable to shareholders of the company	47.12	21.70	+117.1%	29.01	+62.4%
EPS, basic (₹)	2.99	4.17	not comparable	1.82	+64.3%
Net margin (%)	21.7	11.5		14.3

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q4 FY26	Q4 FY25	YoY	Q3 FY26	QoQ
Revenue from operations	210.67	173.87	+21.2%	182.48	+15.4%
Other income	3.72	4.54	−18.1%	3.43	+8.5%
Total income	214.39	178.41	+20.2%	185.91	+15.3%
Profit before tax	61.98	47.80	+29.7%	36.62	+69.3%
Net profit for the period	43.58	21.95	+98.5%	26.15	+66.7%
EPS, basic (₹)	2.75	4.08	not comparable	1.64	+67.7%
Net margin (%)	20.7	12.6		14.3

Consolidated

Filed with BSE: 07 May 2026, 22:52 IST
Board meeting: 07 May 2026
Period: 01 Jan 2026 to 31 Mar 2026
Review status: Audited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 07 May 2026, 22:52 IST
Board meeting: 07 May 2026
Period: 01 Jan 2026 to 31 Mar 2026
Review status: Audited
Source: XBRL filing on BSE